On January 26, 2021 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported that three abstracts from multiple clinical studies will be featured at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC), scheduled for January 28-31, 2021 (Press release, Biodesix, JAN 26, 2021, View Source [SID1234574307]). Findings from these recent studies demonstrate that an individual patient’s immune profile can provide information to support treatment decisions for patients diagnosed with advanced non-small cell lung cancer (NSCLC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These results further demonstrate the importance of understanding a patient’s immune profile as a part of determining appropriate treatment for patients with NSCLC"
MA08.03: Immunotherapy alone or with chemotherapy in advanced NSCLC? Utility of clinical factors and blood-based host immune profiling.
An abstract authored by Wallace Akerley, MD, of the University of Utah Huntsman Cancer Institute demonstrates that host immune classifier (HIC) testing can equip physicians with key information to help guide treatment decisions for patients with newly diagnosed advanced NSCLC.
The prospectively designed INSIGHT observational study (NCT03289780) found that a clinically validated, blood-based HIC successfully helped to predict Immune Checkpoint Inhibition (ICI) therapy outcomes. The HIC test accurately stratified survival for patients receiving ICI but not ICI in addition to platinum-doublet chemotherapy. This suggests that HIC testing can be used to determine the appropriate treatment course for advanced NSCLC patients by identifying patients who may benefit from more aggressive treatment strategies, including ICI plus platinum-based chemotherapy combinations. The highly anticipated abstract for this presentation is part of the conference press program, and therefore under embargo until the presentation at 3:45 a.m. EST on January 30, 2021.
P33.06: Utilizing serum proteome to understand response and resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer
An abstract presented by Won Kyung Hur, MD, of Olive View-UCLA Medical Center, reports data from a study on the Primary Immune Response (PIR) test, a proteomic classifier that identifies an aggressive disease state associated with resistance to ICI therapy. While treatment options for patients with advanced NSCLC have evolved significantly with the introduction of ICI, many patients develop either primary or secondary resistance to ICI, making them unable to benefit from this therapy. Response and resistance to ICI treatment for NSCLC are poorly understood.
This presentation will report findings from an independent validation of the PIR test, led by Young Kwang Chae, MD, which identifies an aggressive NSCLC disease state associated with resistance to ICI therapy. Findings from the study suggest that the PIR test can help predict patient survival with ICI therapy and guide treatment decisions for patients with advanced NSCLC. The data will be available for viewing at 11:00 a.m. EST on January 27, and Dr. Hur will present the data on January 28, 2021.
FP07.17: The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC
The abstract, authored by Eric Schaefer, MD, of Highlands Oncology Group, reports findings from the INSIGHT study, which is evaluating the utility of the Biodesix Lung Reflex testing strategy. The data suggest that using blood-based immune profiling with proteomic testing can help to identify patients with aggressive lung disease at an early stage. This early identification can benefit patients significantly by prompting either enhanced surveillance or additional treatment and may lead to more accurate determination of patient prognosis and classification of disease stages. Dr. Schaefer will present the data on January 28, 2021.
"These results further demonstrate the importance of understanding a patient’s immune profile as a part of determining appropriate treatment for patients with NSCLC," said Scott Hutton, CEO of Biodesix. "By pursuing personalized testing approaches to help guide treatment decisions, we strive to help prevent patients from receiving ineffective and costly care. More than ever, we’re focused on and committed to relentlessly seeking the best treatment plan for every patient with lung cancer. We are tremendously proud to share these new and important study results with the medical community."